Research programme: antibody therapeutics - Genmab/Semaia
Latest Information Update: 16 Jul 2016
At a glance
- Originator Genmab; Semaia Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Denmark
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Netherlands
- 29 Apr 2003 Semaia Pharmaceuticals has been acquired by Hybrigenics